Cargando…

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Junshang, Wang, Jie, Wang, Hui, Jiang, Xianjie, Liao, Qianjin, Gong, Qian, Mo, Yongzhen, Li, Xiaoling, Li, Guiyuan, Xiong, Wei, Zhao, Jin, Zeng, Zhaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959026/
https://www.ncbi.nlm.nih.gov/pubmed/31949496
http://dx.doi.org/10.7150/jca.33105
_version_ 1783487518293884928
author Ge, Junshang
Wang, Jie
Wang, Hui
Jiang, Xianjie
Liao, Qianjin
Gong, Qian
Mo, Yongzhen
Li, Xiaoling
Li, Guiyuan
Xiong, Wei
Zhao, Jin
Zeng, Zhaoyang
author_facet Ge, Junshang
Wang, Jie
Wang, Hui
Jiang, Xianjie
Liao, Qianjin
Gong, Qian
Mo, Yongzhen
Li, Xiaoling
Li, Guiyuan
Xiong, Wei
Zhao, Jin
Zeng, Zhaoyang
author_sort Ge, Junshang
collection PubMed
description Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion: The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.
format Online
Article
Text
id pubmed-6959026
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-69590262020-01-16 The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer Ge, Junshang Wang, Jie Wang, Hui Jiang, Xianjie Liao, Qianjin Gong, Qian Mo, Yongzhen Li, Xiaoling Li, Guiyuan Xiong, Wei Zhao, Jin Zeng, Zhaoyang J Cancer Research Paper Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion: The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer. Ivyspring International Publisher 2020-01-01 /pmc/articles/PMC6959026/ /pubmed/31949496 http://dx.doi.org/10.7150/jca.33105 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Ge, Junshang
Wang, Jie
Wang, Hui
Jiang, Xianjie
Liao, Qianjin
Gong, Qian
Mo, Yongzhen
Li, Xiaoling
Li, Guiyuan
Xiong, Wei
Zhao, Jin
Zeng, Zhaoyang
The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
title The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
title_full The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
title_fullStr The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
title_full_unstemmed The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
title_short The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
title_sort braf v600e mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959026/
https://www.ncbi.nlm.nih.gov/pubmed/31949496
http://dx.doi.org/10.7150/jca.33105
work_keys_str_mv AT gejunshang thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT wangjie thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT wanghui thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT jiangxianjie thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT liaoqianjin thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT gongqian thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT moyongzhen thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT lixiaoling thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT liguiyuan thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT xiongwei thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT zhaojin thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT zengzhaoyang thebrafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT gejunshang brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT wangjie brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT wanghui brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT jiangxianjie brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT liaoqianjin brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT gongqian brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT moyongzhen brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT lixiaoling brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT liguiyuan brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT xiongwei brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT zhaojin brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer
AT zengzhaoyang brafv600emutationisapredictoroftheeffectofradioiodinetherapyinpapillarythyroidcancer